Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) | BIIB Stock NewsStockTitan·1 day ago, 03:30 PMBIIB-1.64%STOK-0.60%
Biogen And Eisai Announce China Approval For Subcutaneous LEQEMBI To Treat Early Alzheimer's Diseaserttnews·2 days ago, 06:06 AMBIIB-1.64%
Biogen: 4-year Data Support Potential Disease-modifying Effects Of Zorevunersenrttnews·Sep 1 at 12:56 PMSTOK-0.60%BIIB-1.64%
Why Veeva Systems (VEEV) Is Up 11.6% After Strong Q2, Higher Guidance, and New AI CRM WinsSimplywall·Aug 30 at 08:21 AMVEEV-3.27%REGN-1.87%
Biogen platforms lupus patient advocate in social media pushFiercepharma·Aug 28 at 01:38 PMBIIB-1.64%
Biogen CEO Viehbacher to speak at Morgan Stanley Global Healthcare ConferencePUBT·Aug 27 at 08:10 PMBIIB-1.64%
4,582 Shares in Biogen Inc. $BIIB Purchased by EFG International AGMarket Beat·Aug 27 at 08:09 AMBIIB-1.64%
Biogen CFO Robin Kramer to join Wells Fargo Healthcare Conference fireside chatPUBT·Aug 26 at 10:59 AMWFC+0.87%BIIB-1.64%
Biogen Inc. Stock Outperforms Competitors On Strong Trading DayMarketWatch Automated·Aug 25 at 08:59 PMBIIB-1.64%
Veeva Vault CRM Selected by Biogen | VEEV Stock NewsStockTitan·Aug 25 at 03:03 AMVEEV-3.27%BIIB-1.64%
Biogen: LEQEMBI IQLIK Autoinjector Available In U.S. For Early Alzheimer'srttnews·Aug 24 at 12:23 PMBIIB-1.64%
